Peripheral Neuropathic Pain – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Peripheral Neuropathic Pain – Pipeline Review, H2 2016’, provides an overview of the Peripheral Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathic Pain

The report reviews pipeline therapeutics for Peripheral Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Peripheral Neuropathic Pain therapeutics and enlists all their major and minor projects

The report assesses Peripheral Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathic Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathic Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Peripheral Neuropathic Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achelios Therapeutics, Inc.

AnaBios Corporation

Chromocell Corporation

GW Pharmaceuticals Plc

Nektar Therapeutics

Phosphagenics Limited

Spherium Biomed S.L.

Sunovion Pharmaceuticals Inc.

Yuhan Corporation

Zynerba Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Peripheral Neuropathic Pain Overview 7

Therapeutics Development 8

Pipeline Products for Peripheral Neuropathic Pain - Overview 8

Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis 9

Peripheral Neuropathic Pain - Therapeutics under Development by Companies 10

Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 11

Peripheral Neuropathic Pain - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Peripheral Neuropathic Pain - Products under Development by Companies 15

Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes 16

Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development 17

Achelios Therapeutics, Inc. 17

AnaBios Corporation 18

Chromocell Corporation 19

GW Pharmaceuticals Plc 20

Nektar Therapeutics 21

Phosphagenics Limited 22

Spherium Biomed S.L. 23

Sunovion Pharmaceuticals Inc. 24

Yuhan Corporation 25

Zynerba Pharmaceuticals, Inc. 26

Peripheral Neuropathic Pain - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

AXPN-03 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CC-8464 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

DSP-2230 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

ECL-1 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ketoprofen - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

nabiximols - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

NKTR-171 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

ORP-101 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

oxycodone ER - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

pregabalin CR - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule 1 for Peripheral Neuropathic Pain - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecule 2 for Peripheral Neuropathic Pain - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecule for Pain - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

SP-15001 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

ZYN-001 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Peripheral Neuropathic Pain - Dormant Projects 63

Peripheral Neuropathic Pain - Discontinued Products 64

Peripheral Neuropathic Pain - Product Development Milestones 65

Featured News & Press Releases 65

Oct 12, 2016: FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN 65

Jul 28, 2014: Phosphagenics Provides Update on TPM/Oxycodone patch 65

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67

List of Tables

List of Tables

Number of Products under Development for Peripheral Neuropathic Pain, H2 2016 8

Number of Products under Development for Peripheral Neuropathic Pain – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Peripheral Neuropathic Pain – Pipeline by Achelios Therapeutics, Inc., H2 2016 17

Peripheral Neuropathic Pain – Pipeline by AnaBios Corporation, H2 2016 18

Peripheral Neuropathic Pain – Pipeline by Chromocell Corporation, H2 2016 19

Peripheral Neuropathic Pain – Pipeline by GW Pharmaceuticals Plc, H2 2016 20

Peripheral Neuropathic Pain – Pipeline by Nektar Therapeutics, H2 2016 21

Peripheral Neuropathic Pain – Pipeline by Phosphagenics Limited, H2 2016 22

Peripheral Neuropathic Pain – Pipeline by Spherium Biomed S.L., H2 2016 23

Peripheral Neuropathic Pain – Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 24

Peripheral Neuropathic Pain – Pipeline by Yuhan Corporation, H2 2016 25

Peripheral Neuropathic Pain – Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Peripheral Neuropathic Pain – Dormant Projects, H2 2016 63

Peripheral Neuropathic Pain – Discontinued Products, H2 2016 64

List of Figures

List of Figures

Number of Products under Development for Peripheral Neuropathic Pain, H2 2016 8

Number of Products under Development for Peripheral Neuropathic Pain – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Top 10 Targets, H2 2016 28

Number of Products by Stage and Top 10 Targets, H2 2016 28

Number of Products by Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports